Patient eligibility
brain disease, allergy, melanoma
INFECTIOUS DISEASES, MELANOMA, ALLERGY, CENTRAL NERVOUS SYSTEM DISEASE, BRAIN DISEASE, RETINAL DISEASE
Eligible patients were aged 18–70 years; histologically or cytologically confirmed, unresectable, stage III or IV melanoma; with Patients were excluded if they had active central nervous system disease except for patients with stable brain disease for ≥ 3 months following stereotactic brain radiotherapy or surgery; inability to swallow or any small intestinal resection that would preclude adequate absorption of the study drug; uncontrolled concomitant or infectious diseases; history of retinal disease; prior treatment with a specific MEK inhibitor; or known allergy to the study drug or its analogs. Strong inducers or inhibitors of CYP isozyme had to be discontinued ≥ 1 week before study treatment.